Physicochemical characterization of nicergoline and cabergoline in its amorphous state

Journal of Thermal Analysis and Calorimetry

Volumn 108, Issue 1, 2012, Pages 323-332

  Martena, Valentina ^a   Censi, Roberta ^a   Hoti, Ela ^b   Malaj, Ledjan ^a,b   Martino, Piera Di ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF TIRANA   (Albania)

Author keywords

Amorphous; Cabergoline; Mean relaxation time constant; Nicergoline; Thermal analysis

Indexed keywords

AGING TIME; AMORPHOUS STATE; CABERGOLINE; DIFFERENTIAL SCANNING CALORIMETRIES (DSC); GLASSY STATE; MEAN RELAXATION TIME CONSTANT; MOLECULAR RELAXATION; NICERGOLINE; ONSET TEMPERATURE; PHYSICAL STABILITY; PHYSICO-CHEMICAL CHARACTERIZATION; PHYSICOCHEMICAL CHARACTERISTICS; SOLID DOSAGE FORMS; SOLVENT EVAPORATION; X-RAY POWDER DIFFRACTOMETRY;

AMORPHOUS MATERIALS; BIOCHEMISTRY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DOSAGE; GLASS TRANSITION; PYRIDINE; THERMOANALYSIS; THERMOGRAVIMETRIC ANALYSIS;

CARBOXYLIC ACIDS;

EID: 84858078659     PISSN: 13886150     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10973-011-1954-2     Document Type: Article

References (46)

1. L Yu 2001 Amorphous pharmaceutical solids: preparation, characterization and stabilization Adv Drug Deliv Rev 48 27 42 10.1016/S0169-409X(01)00098-9 1:CAS:528:DC%2BD3MXivFejsrg%3D (Pubitemid 32454482)
2. BC Hancock 2002 Disordered drug delivery: destiny, dynamics and the Deborah number J Pharm Pharmacol 54 737 746 10.1211/0022357021778989 1:CAS:528:DC%2BD38XkvV2htb4%3D (Pubitemid 34649460)
3. G Chawla AK Bansal 2007 A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug Eur J Pharm Sci 32 45 57 10.1016/j.ejps.2007.05.111 1:CAS:528:DC%2BD2sXotlSgtbs%3D (Pubitemid 47411498)
4. C Leuner J Dressman 2000 Improving drug solubility for oral delivery using solid dispersions Eur J Pharm Biopharm 50 47 60 10.1016/S0939-6411(00) 00076-X 1:CAS:528:DC%2BD3cXjslyju7c%3D (Pubitemid 30326688)
5. AA Ambike KR Mahadik A Paradkar 2004 Stability study of amorphous valdecoxib Int J Pharm 282 151 162 10.1016/j.ijpharm.2004.06.009 1:CAS:528:DC%2BD2cXntVGhsLg%3D (Pubitemid 39178492)
6. T Watanabe N Wakiyama F Usui M Ikeda T Isobe M Senna 2001 Stability of amorphous indomethacin compounded with silica Int J Pharm 226 81 91 10.1016/S0378-5173(01)00776-1 1:CAS:528:DC%2BD3MXmsV2jsb0%3D (Pubitemid 32800785)
7. SL Shimpi B Chauhan KR Mahadik A Paradkar 2005 Stabilization and improved in vivo performance of amorphous etoricoxib using gelucire 50/13 Pharm Res 22 1727 1734 10.1007/s11095-005-6694-1 1:CAS:528:DC%2BD2MXhtVent7vJ (Pubitemid 41355913)
8. Z Gashi R Censi L Malaj R Gobetto M Mozzicafreddo M Angeletti A Masic P Di Martino 2009 Differences in the interaction between arylpropionic acid derivatives and poly(vinylpyrrolidone) K30: a multi-methodological approach J Pharm Sci 98 4216 4228 10.1002/jps.21734 1:CAS:528:DC%2BD1MXhtF2qtLfE
9. C Heitz JJ Descombes RC Miller JC Stoclet 1986 α-adrenoceptor antagonistic and calcium antagonistic effects of nicergoline in the rat isolated aorta Eur J Pharmacol 123 279 285 10.1016/0014-2999(86)90669-2 1:CAS:528:DyaL28XktFyht7c%3D (Pubitemid 16055461)
10. Brossi A. The alkaloids. Chemistry and pharmacology, vol 38. San Diego: Academic Press Inc; 1990. p. 142.
11. Venn RD. Review of clinical studies with ergots in gerontology. In: Goldstein M, Liberman A, Calne DB, Thorner MO, editors. Ergot compounds and brain function. New York: Raven Press; 1980. p. 363-77.
12. D Goo E Palosi L Szporny 1988 Comparison of the effects of vinpocetine, vincamine, and nicergoline on the normal and hypoxia-damaged learning process in spontaneously hypertensive rats Drug Dev Res 15 75 85 10.1002/ddr.430150108 (Pubitemid 19159185)
13. O Pastoris L Vercesi F Allorio M Dossena 1988 Effect of hypoxia, aging and pharmacological treatment on muscular metabolites and enzyme activities Il Farmaco Ed Sci 43 627 642 1:CAS:528:DyaL1cXmt1Ontb0%3D (Pubitemid 18261466)
14. E Triulzi S Devizzi A Margonato 1981 Use of nicergoline in acute myocardial infarction with diastolic hypertension Il Farmaco Ed Prat 36 449 455 1:STN:280:DyaL38%2FntlWnsA%3D%3D (Pubitemid 12179228)
15. M Hušák J Had B Kratochvíl L Cvak J Stuchlík A Jegorov 1994 X-ray absolute structure of nicergoline (form I). Quantitative analysis of nicergoline phase mixture: FormI/form II Collect Czechoslov Chem Commun 59 1624 1636 10.1135/cccc19941624 (Pubitemid 24812437)
16. M Hušák B Kratochvil J Ondraček J Maixner A Jerolov J Stuchlik 1994 The crystal and absolute molecular structure of "low melting" nicergoline (form II) Z Kristallogr 209 260 262 10.1524/zkri.1994.209.3.260
17. E Foresti P Sabatino L Riva di Sanseverino R Fusco C Tosi R Tonani 1988 Structure and molecular orbital study of ergoline derivatives. 1-(6-Methyl-8β-ergolinylmethyl)imidazolidine-2,4-dione (I) and 2-(10-methoxy-1,6-dimethyl-8β-ergolinyl)ethyl 3,5-dimethyl-1H-2- pyrrolecarboxylate toluene hemisolvate (II) and comparison with nicergoline (III) Acta Cryst B44 307 315 1:CAS:528:DyaL1cXks1CktrY%3D
18. L Malaj R Censi D Capsoni L Pellegrino M Bini S Ferrari R Gobetto V Massarotti P Di Martino 2011 Characterization of nicergoline polymorphs crystallized in several organic solvents J Pharm Sci 100 2610 2622 10.1002/jps.22477 1:CAS:528:DC%2BC3MXlslCgs7o%3D
19. A Colao A Di Sarno R Pivonello C Di Somma G Lombardi 2002 Dopamine receptor agonists for treating prolactinomas Expert Opin Investig Drugs 11 787 800 10.1517/13543784.11.6.787 1:CAS:528:DC%2BD38Xks1Ojsbw%3D (Pubitemid 34618811)
20. CW Olanow 2004 The scientific basis for the current treatment of Parkinson's disease Ann Rev Med 55 41 60 10.1146/annurev.med.55.091902.104422 1:CAS:528:DC%2BD2cXitVWrtLc%3D (Pubitemid 38316715)
21. P Sabatino L Riva Di Sanseverino R Tonani 1995 X-ray crystal structure and conformational analysis of N-(3-dimethylaminopropyl)-N-(ethylaminocarbonyl)- 6-(2-propenyl)ergoline-8β-carboxamide (cabergoline): comparison with bromocriptine and lisuride and a hypothesis for its high dopaminergic activity Il Farmaco 50 175 178 1:CAS:528:DyaK2MXltFGnurw%3D
22. R Bednář L Cvak J Čejka B Kratochvíl I Císařová A Jegorov 2004 Cabergoline, form VII Acta Cryst E60 o1167 o1169
23. A Jegorov L Cvak R Bednář J Čejka M Hušák B Kratochvíl I Císařová 2006 Structures of cabergoline anhydrate form II and novel cabergoline solvates Struct Chem 17 131 137 10.1007/s11224-006-9043-z 1:CAS:528:DC%2BD28XlvFSqu7k%3D (Pubitemid 43882065)
24. BC Hanckock G Zografi 1997 Characteristics and significance of the amorphous state J Pharm Sci 6 1 12 10.1021/js9601896
25. P Di Martino GF Palmieri S Martelli 2000 Molecular mobility of the paracetamol amorphous form Chem Pharm Bull 48 1105 1108 10.1248/cpb.48.1105 1:CAS:528:DC%2BD3cXlsFCqtrw%3D (Pubitemid 30660266)
26. J Cao Y Long RA Shanks 1997 Experimental investigation into the heat capacity measurement using an modulated DSC J Therm Anal Calorim 50 365 373 10.1007/BF01980497 1:CAS:528:DyaK2sXmvVWitr8%3D (Pubitemid 127789252)
27. R Venkata Krishnan K Nagarajan 2010 Evaluation of heat capacity measurements by temperature-modulated differential scanning calorimetry J Therm Anal Calorim 102 1135 1140 10.1007/s10973-010-0770-4 1:CAS:528: DC%2BC3cXhsVCrsbvM
28. G Zografi 1988 States of water associated with solids Drug Dev Ind Pharm 14 1905 1926 10.3109/03639048809151997 1:CAS:528:DyaL1cXlvFOktbk%3D
29. C Ahlneck G Zografi 1990 The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state Int J Pharm 62 87 95 10.1016/0378-5173(90)90221-O 1:CAS:528:DyaK3cXlslyjurg%3D (Pubitemid 20261777)
30. V Andronis M Yoshioka G Zografi 1997 Effect of sorbed water on crystallization of indomethacin from the amorphous state J Pharm Sci 86 346 351 10.1021/js9602711 1:CAS:528:DyaK2sXhtVGhtrs%3D (Pubitemid 27113770)
31. E Schmitt CW Davis ST Long 1996 Moisture-dependent crystallization of amorphous lamotrigine mesylate J Pharm Sci 85 1215 1219 10.1021/js9600484 1:CAS:528:DyaK28XmtFKisrw%3D (Pubitemid 26372891)
32. P Tong G Zografi 1999 Solid-state characteristics of amorphous indomethacin relative to its free acid Pharm Res 16 1186 1192 10.1023/A:1018985110956 1:CAS:528:DyaK1MXlsVynt7k%3D (Pubitemid 29393605)
33. L Gunawan GP Johari RM Shanker 2006 Structural relaxation of acetaminophen glass Pharm Res 23 967 979 10.1007/s11095-006-9898-0 1:CAS:528:DC%2BD28XkslKjt7k%3D (Pubitemid 43781405)
34. Di Martino P. Crystal growth from pharmaceutical melts. In: Seifer ED, editor. Bosons, ferromagnetism and crystal growth research. Horizons in world physics, vol. 257. New York: Nova Publisher; 2007. p. 221-45.
35. G Van den Mooter P Augustijns R Kinget 1999 Stability prediction of amorphous benzodiazepines by calculation of the mean relaxation time constant using the Williams-Watts decay function Eur J Pharm Biopharm 48 43 48 10.1016/S0939-6411(99)00013-2 (Pubitemid 29308924)
36. g with that of structural analogues using MTDSC Int J Pharm 213 163 173 10.1016/S0378-5173(00)00662-1 1:CAS:528: DC%2BD3MXmvFOjsg%3D%3D (Pubitemid 32119472)
37. K Vasukumar AK Bansal 2002 Enthalpy relaxation studies on celecoxib amorphous mixtures Pharm Res 19 1873 1878 10.1023/A:1021453810624 (Pubitemid 36016036)
38. PJ Marsac H Konno LS Taylor 2006 A comparison of the physical stability of amorphous felodipine and nifedipine systems Pharm Res 23 2306 2316 10.1007/s11095-006-9047-9 1:CAS:528:DC%2BD28XhtVeqsbvN (Pubitemid 44511511)
39. S Montserrat 1994 Physical aging studies in epoxy resins. I. Kinetics of the enthalpy relaxation process in a fully cured epoxy resin J Polym Sci B Polym Phys 32 509 522 10.1002/polb.1994.090320312 1:CAS:528:DyaK2cXhtlGqtL4%3D
40. E Fukuoka M Makita S Yamamura 1989 Glassy state of pharmaceuticals. III. Thermal properties and stability of glassy pharmaceuticals and their binary glass systems Chem Pharm Bull 37 1047 1050 10.1248/cpb.37.1047 1:CAS:528:DyaL1MXkt1ynsbg%3D (Pubitemid 19144144)
41. M Yoshioka BC Hancock G Zografi 1994 Crystallization of indomethacin from the amorphous state below and above its glass transition temperature J Pharm Sci 83 1700 1705 10.1002/jps.2600831211 1:CAS:528:DyaK2cXms1entrY%3D
42. BC Hancock SL Shamblin G Zografi 1995 Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures Pharm Res 12 799 806 10.1023/A:1016292416526 1:CAS:528:DyaK2MXmtV2qurg%3D
43. C Bauwens-Crowet JC Bauwens 1986 Annealing of polycarbonate below the glass transition temperature Polymer 27 709 713 10.1016/0032-3861(86)90128-X 1:CAS:528:DyaL28XksVeksbw%3D (Pubitemid 16537772)
44. DJ Kemmish JN Hay 1985 The effect of physical ageing on the properties of amorphous PEEK Polymer 26 905 912 10.1016/0032-3861(85)90136-3 1:CAS:528:DyaL2MXkslWqt74%3D (Pubitemid 16459332)
45. G Williams DC Watts 1970 Non-symmetrical dielectric relaxation behaviour arising from a simple empirical decay function Trans Faraday Soc 66 80 85 10.1039/tf9706600080 1:CAS:528:DyaE3cXotlyrsA%3D%3D
46. K) of amorphous pharmaceuticals Pharm Res 15 1649 1650 10.1023/A:1011983923386 1:CAS:528:DyaK1cXnsFSgu7Y%3D (Pubitemid 28524571)